Liver transplantation for alcoholic hepatitis: A systematic review with meta-analysis

Astrid Marot1, Margaux Dubois1, Eric Trépo2,3, Christophe Moreno2,3, Pierre Deltenre1,2*

1 Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland, 2 Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, 3 Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, Brussels, Belgium

*pierre.deltenre01@gmail.com

Abstract

Background
The rate of alcohol relapse among patients who underwent liver transplantation for alcoholic hepatitis (AH) is not precisely known.

Aim
Synthesize the available evidence on liver transplantation for AH to assess alcohol relapse and 6-month survival.

Methods
Meta-analysis of trials evaluating liver transplantation for AH, either clinically severe or diagnosed on the explant.

Results
Eleven studies were included. The pooled estimate rate for alcohol relapse was 0.22 (95% CI = 0.12–0.36) in overall analysis with high heterogeneity between studies ($I^2 = 76\%$), 0.20 (95% CI = 0.07–0.43) in the subgroup analysis including patients with clinically severe AH ($I^2 = 84\%$), 0.14 (95% CI = 0.08–0.23) among patients with clinically severe AH in sensitivity analysis excluding the discrepant studies that did not use stringent selection criteria for liver transplantation ($I^2 = 0\%$), and 0.15 (95% CI = 0.07–0.27) for recurrent harmful alcohol consumption among patients with clinically severe AH ($I^2 = 3\%$). The risk of alcohol relapse was not different between AH transplanted patients and patients with alcoholic cirrhosis who underwent elective liver transplantation in sensitivity analysis excluding the discrepant studies (OR = 1.68, 95% CI = 0.79–3.58, $p = 0.2$, $I^2 = 16\%$). The pooled estimate rate for 6-month survival was 0.85 (95% CI = 0.77–0.91, $I^2 = 49\%$), and 0.80 among patients transplanted for clinically severe AH (95% CI = 0.69–0.88, $I^2 = 30\%$). AH transplanted patients had similar 6-month survival to patients with alcoholic cirrhosis who underwent elective liver transplantation (OR = 2.00, 95% CI = 0.95–4.23, $p = 0.07$, $I^2 = 0\%$).
Conclusion

Using stringent selection criteria, 14% of patients with clinically severe AH have alcohol relapse after liver transplantation. The percentage of alcohol relapse of AH transplanted patients is similar than that of patients who underwent elective liver transplantation.

Introduction

The treatment of severe forms of alcoholic hepatitis (AH) remains a challenge, especially for non-responders to corticosteroids who only have a 25% survival probability at 6 months [1]. In the absence of another therapeutic option, liver transplantation has been proposed in this setting. In a recent study, the 6-month survival of patients with a first episode of severe AH not responding to medical therapy who underwent early liver transplantation was significantly better than that for non-responders who were not transplanted [2]. This study challenged the rule that a 6-month period of abstinence should be required before considering liver transplantation for patients with alcoholic liver disease.

The reasons why a 6-month abstinence period is usually applied before considering a patient with alcoholic liver disease for liver transplantation are manifold. They include hope that liver function will improve after alcohol withdrawal, fear of recurrent alcohol consumption after liver transplantation, organ shortages, and fear that considering liver transplantation in patients with a self-inflicted disease could raise a problem of equity in liver graft allocation and in both public opinion and healthcare providers who participate in candidate selection [3, 4]. However, a recent survey indicated that early liver transplantation for carefully selected patients with acute AH was not as controversial with the public as previously thought [5]. In addition, only a few patients with severe AH returned to alcohol consumption after liver transplantation in recent studies that applied strict selection criteria for choosing candidates [2, 6, 7]. Finally, previous studies among patients with alcoholic cirrhosis have indicated that the 6-month rule of abstinence poorly identifies patients with recurrent alcohol consumption after liver transplantation [8, 9]. In the setting of liver transplantation for patients with AH, in addition to the studies performed in patients with severe AH, a couple of studies have also identified AH on explants from patients with alcoholic liver disease, suggesting that these patients probably did not fulfill the 6-month abstinence rule before liver transplantation [10, 11]. These studies provide additional data on alcohol relapse following liver transplantation for AH.

Despite the large amount of data on liver transplantation for AH that already exists, the rate of recurrent alcohol consumption after liver transplantation among patients with AH is still not precisely known. Meta-analysis is a quantitative technique that enables pooling data from trials in order to decrease random error. It also allows for assessment of the magnitude of impact of a particular factor. In this study, we performed a meta-analysis of trials evaluating liver transplantation among patients with AH. Our main objective was to assess the rate of alcohol relapse among AH transplanted patients and to compare it to alcohol relapse rates among patients with alcoholic cirrhosis who underwent elective liver transplantation. Our secondary objectives were to assess the rates of harmful alcohol relapse and 6-month survival among AH transplanted patients, and to compare 6-month survival rates among AH transplanted patients to those of non-responders who were not transplanted or to patients with alcoholic cirrhosis who underwent elective liver transplantation.
**Materials and methods**

**Literature search**

Medline (PubMed), Embase, Cochrane library, and manual searches were combined and last performed on June 10th, 2017. Key search terms were “alcoholic hepatitis”, “abstinence”, “alcohol relapse”, and “liver transplantation”. Terms were combined within each database. General reviews and references from published trials were also used. The exact search term combinations can be found in the S1 Appendix. Duplicate were excluded. No language restriction was applied. Two observers (A.M. and M.D.) also screened all abstracts presented between 2014 and 2017 at the Liver Meeting of the American Association for the Study of Liver Diseases (AASLD) and the International Liver Congress of the European Association for the Study of the Liver (EASL).

**Criteria for inclusion and exclusion of studies**

All observational studies were included. In order to reduce risk of bias, strict inclusion and exclusion criteria were defined prior to the literature search. To be considered, a study had to: a) include patients with AH, either patients with acute jaundice and severe AH or patients with alcoholic cirrhosis who underwent a liver transplantation and in whom the diagnosis of AH was made on the explant; b) provide data relative to alcohol consumption or survival after liver transplantation. When several publications were found covering the same study population, only the most recent was taken into account.

**Endpoints**

Endpoints were defined prior to the beginning of the meta-analysis. The main endpoint was alcohol relapse defined as any alcohol consumption after liver transplantation. The secondary endpoints were harmful drinking defined as binge, frequent, regular or daily drinking, and 6-month survival.

**Data extraction**

Data extraction was performed independently by two investigators (A.M. and M.D.) using standardized data collection forms. Discrepancies in data interpretation were resolved by discussion, re-review of the studies and consultation with one other author (P.D.) when necessary.

**Quality score**

The methodological quality of studies was assessed using the Newcastle Ottawa Scale for cohort studies [12].

**Statistical analysis**

We used a random effects model to obtain a summary estimate of primary outcomes among patients with AH. The random-effects model was chosen because it takes into account the possibility of heterogeneity between studies [13]. Data on all patients were extracted to allow intention-to-treat analyses. We calculated event rates among patients with AH, a measure of how often a particular statistical event occurs within a group in an experiment, with 95% confidence intervals (CI), as already done elsewhere [14–16]. Differences between groups are expressed as odds ratios (ORs) with 95% CIs. A p-value <0.05 was considered statistically significant.

As a first step, an overall meta-analysis was performed. This analysis included transplanted patients with clinically severe AH and transplanted patients in whom the diagnosis of AH was...
made on the explant. In a second step, subgroup analyses in patients with and without clinically severe AH were performed. The overall analysis also included studies comparing AH transplanted patients to non-responders to medical therapy who were not transplanted, or to patients with alcoholic cirrhosis but without AH who underwent elective liver transplantation. In a third step, subgroup analyses comparing AH transplanted patients to non-responders to medical therapy who were not transplanted or to patients with alcoholic cirrhosis but without AH who underwent elective liver transplantation were performed.

Heterogeneity was assessed by Cochran’s Q test [17] and the \( I^2 \) statistic. More specifically, the \( I^2 \) statistic was used to estimate inconsistency in the meta-analysis, representing the percentage of the between-study variability due to heterogeneity rather than chance [18]. A significant Cochran’s Q-statistic (below 0.10) was chosen as a threshold for significant heterogeneity across studies. The following cut-offs were used to quantify heterogeneity with the \( I^2 \) statistic: 0–25%, low; 25–50%, moderate; >50%, high heterogeneity [18]. In cases of moderate or high heterogeneity, the methodological section of each study was re-reviewed to determine whether any discrepancy could be identified, and sensitivity analyses excluding the discrepant study were performed. To assess the extent of publication bias, the Egger test, the Begg and Mazumdar test and the Trim and Fill adjustment were used [17, 19]. A p-value <0.05 was considered statistically significant. All statistical analyses were performed using Comprehensive Meta-analysis (Biostat, Englewood, NJ).

**Results**

**Study population**

Fig 1 summarizes the flow chart of the selection of studies for inclusion in the meta-analysis. We screened 1130 references; 485 were selected for full-text retrieval. Of these, 11 were included in the analysis [2, 7, 10, 11, 20–26]. One study [27] which was a national registry that included patients from 2 other studies [7, 21] was excluded to avoid duplication of data.

Table 1 summarizes the main characteristics of the studies included in the meta-analysis. A total of 325 patients with AH were included. There were 240 patients with clinically severe AH and 85 patients in whom the diagnosis of AH was made on the explant.

**Study quality**

S1 Table details the quality of the studies included.

**Methodological assessment of studies**

With the exception of the Mathurin’s study [2], all studies were retrospective (Table 1). The methodological analysis of each study identified discrepancies in 2 of them [22, 25]. In these studies, either active consumers or patients abstinent only for a very short period of time were intentionally transplanted without using stringent criteria for selecting candidates for liver transplantation as has been done in the most recent studies (Table 1). These criteria included patients’ motivation to stay abstinent of alcohol following liver transplantation, a good psychosocial support and/or a favorable patient psychological profile. In cases of moderate or high heterogeneity in subgroup analyses, sensitivity analyses excluding the Shakil [22] and the Van Thiel [25] studies were performed.

**Outcomes**

**Risk of alcohol relapse after liver transplantation.** The pooled estimate rate for alcohol relapse was 0.22 (95% CI = 0.12–0.36, Fig 2 and Table 2). There was high heterogeneity
between studies ($p < 0.001, I^2 = 76\%$). Publication bias was detected by the Egger test ($p = 0.02$) but not by the Begg and Mazumdar test ($p = 0.7$). Funnel plot are shown in S1 Fig, including results using the Trim and Fill adjustment.

Results of subgroup analyses including only patients with clinically severe AH are reported as Supporting Information (S2 Table). The pooled estimate rate for alcohol relapse was 0.20 (95% CI = 0.07–0.43). There was high heterogeneity between studies ($p < 0.001, I^2 = 84\%$). In sensitivity analysis excluding studies that did not use stringent criteria for selecting candidates for liver transplantation, the pooled estimate rate for alcohol relapse was 0.14 (95% CI = 0.08–0.23), with no heterogeneity between studies ($p = 0.6, I^2 = 0\%$). The rate for harmful alcohol relapse was 0.15 (95% CI = 0.07–0.27), with negligible heterogeneity between studies ($p = 0.4, I^2 = 3\%$).

Results of subgroup analyses including only patients in whom the diagnosis of AH was made on the explant are reported as Supporting Information (S2 Table). The pooled estimate rate for alcohol relapse was 0.23 (95% CI = 0.11–0.43). There was high heterogeneity between
Table 1. Characteristics of the 11 included studies.

| References     | Study design | N of patients with AH | Type of AH | Age (years) | Male (%) | Histologically proven AH | Duration of abstinence before liver transplantation | Criteria for selecting patients for liver transplantation | MELD score | Maddrey DF |
|----------------|--------------|-----------------------|------------|-------------|----------|--------------------------|-----------------------------------------------------|------------------------------------------------------|------------|------------|
| Hanouneh 2014 (20) | Retrospective | 29                    | Severe     | NA          | NA       | NA                       | NA                                                  | NA                                                  | 3/4        | 35         | 110        |
| Im 2016 (21)    | Retrospective | 16                    | Severe     | 41*         | 56%      | Yes                      | 33 days before listing for liver transplantation * * | Yes in 89% of patients * *                            | 4/4        | 39*        | 92*        |
| Immordino 2009 (10) | Retrospective | 8                     | Diagnosed on the liver explant | 53*       | 86%      | Yes                      | NA                                                  | --                                                  | 14 **      | NA         |
| Lee 2017 (7)    | Retrospective | 17                    | Severe     | 50*         | 76%      | Yes                      | 40 days                                             | Yes                                                 | 4/4        | 37*        | 67*        |
| Mathurin 2011 (2) | Prospective  | 26                    | Severe     | 47*         | 58%      | Yes                      | <3 months                                           | Yes                                                 | 4/4        | 34*        | 76*        |
| Shakil 1997 (22) | Retrospective | 9**                   | Diagnosed on the liver explants | 41*       | 89%      | Yes                      | ≤1 month for 6 patients                             | --                                                  | NA         | 47**       |
| Siddachari 2014 (23) | Retrospective | 33                    | Severe     | 46**        | NA       | NA                       | NA                                                  | NA                                                  | 2/4        | 30 **      | 91**       |
| Singal 2012 (24) | Retrospective | 55                    | Severe     | 52*         | 76%      | No for most of the patients | <3 months                                           | Well-selected group of AH patients                   | 26 **      | NA         |
| Tome 2002 (25)  | Retrospective | 36                    | Diagnosed on the liver explant | 51*       | 92%      | Yes                      | 15 months                                           | --                                                  | NA         | 72% <32    | 28% ≥32    |
| Van Thiel 1995 (26) | Retrospective | 64                    | Severe     | 47*         | 73%      | Yes                      | All patients were active consumers                   | NA                                                  | NA         | NA         |
| Wells 2007 (26) | Retrospective | 32                    | Diagnosed on the explant | 50**       | 69%      | Yes                      | 9.7 months                                           | --                                                  | 21 **      | 38*        |

Abbreviations: NA, not available; AH, alcoholic hepatitis
* Expressed as median
** Expressed as mean
* Data extracted from ref. [6]
** Data extracted from the whole study population transplanted
*** Missing values in 2 patients
**** Data at the first day of medical therapy
† Sobriety contract means oral or written contract agreeing to stay abstinent of alcohol after liver transplantation
‡‡‡ 17 patients had typical histological features AH on the liver explants but only 9 patients fulfilled the criterion of severe AH with DF > 32 and were analyzed in this study

https://doi.org/10.1371/journal.pone.0190823.t001
studies (p = 0.09, I² = 54%). In sensitivity analysis excluding studies that did not use stringent criteria for selecting candidates for liver transplantation, the pooled estimate rate for alcohol relapse was 0.19 (95% CI = 0.08–0.38), with high heterogeneity between studies (p = 0.1, I² = 54%). The rate for harmful alcohol relapse was not assessed in this subgroup analysis due to the limited number of studies with available data.

AH transplanted patients had a non-significantly different risk of alcohol relapse compared to patients with alcoholic cirrhosis who underwent elective liver transplantation (OR = 2.28, 95% CI = 0.98–5.29, p = 0.055), with high heterogeneity between studies (p = 0.05, I² = 59%). In the sensitivity analysis excluding studies that did not use stringent criteria for selecting candidates for liver transplantation, AH transplanted patients had a similar risk of alcohol relapse compared to patients with alcoholic cirrhosis who underwent elective liver transplantation (OR = 1.68, 95% CI = 0.79–3.58, p = 0.2, Fig 3), with low heterogeneity between studies (p = 0.3, I² = 16%). Subgroup analysis including only patients with severe AH was not done due to the limited number of studies with available data. In the subgroup analysis including only patients in whom the diagnosis of AH was made on the explants, the risk of alcohol relapse was higher among AH transplanted patients than in those who underwent elective liver transplantation (OR = 2.3, 95% CI = 1.08–4.89, p = 0.03), with no heterogeneity among studies (p = 0.4, I² = 0%).

6-month survival. The pooled estimate rate for 6-month survival was 0.85 (95% CI = 0.77–0.91, Fig 4 and Table 2). There was high heterogeneity between studies (p = 0.05, I² = 49%). Publication bias was detected by the Egger test (p = 0.01) and by the Begg and Mazumdar test (p = 0.06). Funnel plot are shown in S2 Fig, including results using the Trim and Fill adjustment.
Results of subgroup analyses including only patients with clinically severe AH are reported as Supporting Information (S2 Table). The pooled estimate rate for 6-month survival was 0.80 (95% CI = 0.69–0.88), with moderate heterogeneity between studies ($p = 0.2$, $I^2 = 30\%$).

Table 2. Alcohol relapse and 6-month survival after liver transplantation among the 11 included studies.

| References | Groups of patients | N  | Alcohol relapse (n) | Harmful alcohol relapse (n) | 6-month survival (%) |
|------------|--------------------|----|---------------------|---------------------------|----------------------|
| Hanouneh 2014 (20) | AH transplanted patients | 29 | NA $^\dagger$ | NA | 87% |
| Im 2016 (21) | AH transplanted patients | 16 | 2 | 2 $^\ddagger$ | 88% |
| | Non-responders to corticoids who were not transplanted | 152 | – | – | 19% |
| Immordino 2009 (10) | AH transplanted patients | 8 | 1 | NA | NA |
| | Patients with alcoholic cirrhosis who were transplanted | 102 | 12 | NA | NA |
| Lee 2017 (7) | AH transplanted patients | 17 | 4 | 4 $^\ddagger\ddagger$ | 100% |
| | Patients with alcoholic cirrhosis who were transplanted | 26 | 7 $^*$ | 3 $^\ddagger\ddagger$ | 88% |
| Mathurin 2011 (2) | AH transplanted patients | 26 | 3 | 2 $^\ddagger\ddagger\ddagger$ | 77% |
| | Non-responders to corticoids who were not transplanted | 26 | – | – | 23% |
| Shakil 1997 (22) | AH transplanted patients | 9 | 3 $^\ddagger\ddagger$ | NA | 89% |
| Siddachari 2014 (23) | AH transplanted patients | 33 | 3 | NA | 70% |
| | Patients with alcoholic cirrhosis who were transplanted | 127 | 11 | NA | NA |
| Singal 2012 (24) | AH transplanted patients | 55 | NA | NA | 95% $^{***}$ |
| | Patients with alcoholic cirrhosis who were transplanted | 165 | NA | NA | 90% $^{***}$ |
| Tomé 2002 (11) | AH transplanted patients | 36 | 4 | NA $^{****}$ | 79% $^{***}$ |
| | Patients with alcoholic cirrhosis who were transplanted | 32 | 3 | NA $^{****}$ | 72% $^{***}$ |
| Van Thiel 1995 (25) | AH transplanted patients | 64 | 33 | NA | NA |
| | Patients with alcoholic cirrhosis who were transplanted | 145 | 22 | NA | NA |
| Wells 2007 (26) | AH transplanted patients | 32 | 10 | 8 $^{\\ddagger\\ddagger\\ddagger}$ | 96% $^{***}$ |
| | Patients with alcoholic cirrhosis who were transplanted | 116 | 14 | 12 $^{\\ddagger\ddagger\ddagger\ddagger}$ | 86% $^{***}$ |

Abbreviations: NA, not available; AH, alcoholic hepatitis

$^\dagger$ Data among 24 patients (2 patients who died during the immediate postoperative period were excluded from this analysis)

$^\ddagger$ Data on alcohol relapse available in only 6 patients

$^{***}$ Data extrapolated from survival curves

$^{****}$ In ref. [11], data on harmful alcohol relapse are pooled for AH patients and patients with alcoholic cirrhosis

$^\ddagger$ Discordant results in the abstract did not allow for extraction of accurate data

$^{\ddagger\ddagger}$ Alcohol relapse was defined as alcohol consumption of 4 or more drinks in a day or at least one drink for 4 or more days in succession after liver transplantation (harmful drinking)

$^{\ddagger\ddagger\ddagger}$ Harmful alcohol relapse was defined as alcohol relapse with binge drinking or frequent patterns defined as any alcohol consumption on 4 days in a week

$^{\ddagger\ddagger\ddagger\ddagger}$ Harmful alcohol relapse was defined as daily alcohol consumption

$^{\ddagger\ddagger\ddagger\ddagger\ddagger}$ Harmful alcohol relapse was defined as $\geq$6 alcoholic drinks in one day

https://doi.org/10.1371/journal.pone.0190823.t002
Results of subgroup analyses including only patients in whom the diagnosis of AH was made on the explant are reported as Supporting Information (S2 Table). The pooled estimate rate for 6-month survival was 0.90 (95% CI = 0.76–0.97), with high heterogeneity between studies ($p = 0.06$, $I^2 = 60\%$). In sensitivity analysis excluding studies that did not use stringent criteria for selecting candidates for liver transplantation, the pooled estimate rate for 6-month survival was 0.91 (95% CI = 0.72–0.98), with high heterogeneity between studies ($p = 0.02$, $I^2 = 73\%$).

Fig 3. Risk of alcohol relapse after liver transplantation between AH transplanted patients and patients with alcoholic cirrhosis who underwent elective liver transplantation in sensitivity analysis excluding studies that did not use stringent criteria for selecting candidates for liver transplantation. CI, confidence interval; OR, odds ratio.

https://doi.org/10.1371/journal.pone.0190823.g003

Results of subgroup analyses including only patients in whom the diagnosis of AH was made on the explant are reported as Supporting Information (S2 Table). The pooled estimate rate for 6-month survival was 0.90 (95% CI = 0.76–0.97), with high heterogeneity between studies ($p = 0.06$, $I^2 = 60\%$). In sensitivity analysis excluding studies that did not use stringent criteria for selecting candidates for liver transplantation, the pooled estimate rate for 6-month survival was 0.91 (95% CI = 0.72–0.98), with high heterogeneity between studies ($p = 0.02$, $I^2 = 73\%$).

Fig 4. Pooled estimate rate for survival at 6 months among AH transplanted patients. CI, confidence interval.

https://doi.org/10.1371/journal.pone.0190823.g004
AH transplanted patients had better 6-month survival than did non-responders to corticoids who were not transplanted (OR = 16.69, 95% CI = 6.21–44.81, p < 0.001), with no heterogeneity between studies (p = 0.3, $I^2 = 0\%$).

AH transplanted patients had similar 6-month survival compared to patients with alcoholic cirrhosis who underwent elective liver transplantation (OR = 2.00, 95% CI = 0.95–4.23, p = 0.07), with no heterogeneity between studies (p = 0.7, $I^2 = 0\%$). Subgroup analyses including only patients with severe AH were not done due to the limited number of studies with available data. In the subgroup analysis including only patients in whom the diagnosis of AH was made on the explants, AH patients had similar 6-month survival compared to patients who underwent elective liver transplantation (OR = 1.88, 95% CI = 0.87–4.07, p = 0.1), with no heterogeneity among studies (p = 0.6, $I^2 = 0\%$).

**Discussion**

The increasing recognition of liver transplantation as a rescue therapy for patients with severe AH not responding to medical therapy has challenged the 6-month rule of abstinence. This rule, which poorly identifies patients with alcoholic liver disease who will have recurrent alcohol use after liver transplantation [8, 9], is not applicable to patients with severe AH who have no other therapeutic option and who have a high risk of death within 6 months after the onset of the disease. Since the landmark study of Mathurin et al. in 2011 [2], several teams have reported their first experience with early liver transplantation among patients with severe AH. In addition, a couple of studies have reported on the outcomes of patients transplanted for alcoholic cirrhosis in which AH was discovered on the explants. Despite using a different selection process than the one used for patients with clinically severe AH, these studies provide additional data on the behavior of AH patients following liver transplantation. As a result, there are quite a lot of data currently available on the risk of alcohol relapse among AH transplanted patients. Thus, a meta-analysis is required to synthesize available data.

This meta-analysis found that only one-fifth of AH patients had alcohol relapse after liver transplantation. The percentage of AH transplanted patients with alcohol relapse was not significantly different than that of patients with alcoholic cirrhosis who underwent elective liver transplantation with the exception of patients in whom the diagnosis of AH was made on the explant. In these cases, proper selection of candidates for liver transplantation was less likely than in patients not responding to corticosteroids and who, in the end, were transplanted. Of note, after the exclusion of a discrepant study that did not use stringent criteria for selecting candidates for liver transplantation, only 14% of patients with clinically severe AH had alcohol relapse after liver transplantation. However, in cases of recurrence, most patients had harmful drinking patterns as has already been shown for patients transplanted for alcoholic cirrhosis after a 6-month sobriety period [28]. Overall, these results indicate that the selection of AH patients for liver transplantation should be based on stringent criteria, as has been done in the most recent studies [2, 6]. Currently, the use of such strict selection process seems to be a key factor that allows for selection of patients with a low risk of alcohol relapse after liver transplantation.

This meta-analysis confirmed that liver transplantation considerably improved the prognosis of patients with severe AH who were not responding to medical therapy. The pooled estimate rate for survival was 85% at 6 months among all AH transplanted patients and 80% among patients with clinically severe AH. This was much better than the rate for non-transplanted non-responder patients. In addition, AH transplanted patients had similar 6-month survival compared to patients with alcoholic cirrhosis who underwent elective liver transplantation. However, data on long-term prognosis were not available. This could be a matter of
concern among AH patients with recurrent alcohol consumption as alcohol relapse is likely to impact long-term prognosis. Nevertheless, as liver transplantation can only be proposed to a limited number of patients, alternative pharmacological therapies should be developed for patients who are not responding to medical therapy to reduce the number of potential candidates for liver transplantation.

We acknowledge that this meta-analysis has several limitations. One set of limitations is related to the fact that AH was not confirmed with a liver biopsy in all patients with clinically severe AH, to the retrospective design of most studies, and to the limited number of patients. However, it was expected that most studies dealing with non-responder transplanted AH patients were retrospective and included few patients. In addition, individual participant data and data related to the effect of alcohol relapse according to the pattern of drinking would have been of interest but, unfortunately, they were not available. Another limitation is the existence of publication bias detected regarding the risk of alcohol relapse and 6-month survival, despite our efforts to limit this risk as much as possible using a number of methods. However, the impact of this bias was probably modest. Another issue lies with the criteria used for selecting patients for liver transplantation that were not uniform between studies. A classical limitation of meta-analyses is also related to the presence of heterogeneity that may prevent making robust conclusions and recommendations. This suggests that a substantial proportion of the difference in the effect between studies cannot only be explained by random sampling but by true differences between studies. In this meta-analysis, high heterogeneity was found for several analyses on the risk of alcohol relapse and survival. However, heterogeneity was always reduced and even disappeared in subgroup analyses or when discrepant studies that did not use stringent criteria for selecting candidates for liver transplantation were excluded. Therefore, the results of these analyses seem robust for assessment of the rate of alcohol relapse among AH transplanted patients even if they are based on a limited number of studies. Nevertheless, prospective studies using stringent selection criteria are still needed. In line with this, the first results of an ongoing prospective observation trial focusing on alcohol relapse after liver transplantation (NCT01756794) expected at the beginning of 2018 will be of interest. This study may contribute to the identification of factors predicting alcohol relapse after liver transplantation in daily practice.

In summary, 14% of carefully selected patients with clinically severe AH not responding to medical therapy have alcohol relapse after liver transplantation. When rigorous criteria for selecting candidates for liver transplantation are applied, the percentage of alcohol relapse of AH transplanted patients is not different than that of patients with alcoholic cirrhosis who underwent elective liver transplantation. Stringent selection criteria should be defined and applied when considering liver transplantation in patients with AH.

Supporting information

S1 Fig. Funnel plot of studies evaluating alcohol relapse. As the shape of the funnel plot for the studies was not symmetrical, the Duval and Tweedie’s Trim and Fill adjustment was used to estimate the extent of the impact of the bias and what the effect size would have been in the absence of bias. It re-computes the effect size at each iteration until the funnel plot is symmetric about the new effect size. The observed studies are shown as open white circles and the observed point estimate in log units is shown as an open white diamond, while the imputed studies are shown in red open circles and the imputed point estimate in log units is shown as a red diamond. Overall, the impact of bias was probably modest. (TIFF)
S2 Fig. Funnel plot of studies evaluating 6-month survival. As the shape of the funnel plot for the studies was not symmetrical, the Duval and Tweedie’s Trim and Fill adjustment was used to estimate the extent of the impact of the bias and what the effect size would have been in the absence of bias. It re-computes the effect size at each iteration until the funnel plot is symmetric about the new effect size. The observed studies are shown as open white circles and the observed point estimate in log units is shown as an open white diamond, while the imputed studies are shown in red open circles and the imputed point estimate in log units is shown as a red diamond. Overall, the impact of bias was probably modest.

S1 Table. Quality assessment of the 11 included studies using the Newcastle Ottawa Scale. NA, not applicable.

S2 Table. Results of subgroup analyses including only patients with clinically severe AH or in whom the diagnosis of AH was made on the explants. AH, alcoholic hepatitis; CI, confidence interval.

Acknowledgments
The authors thank Sandy Field, Ph.D. for her help with English-language editing

Author Contributions
Conceptualization: Pierre Deltenre.
Data curation: Astrid Marot, Margaux Dubois, Pierre Deltenre.
Formal analysis: Astrid Marot, Eric Trépo, Christophe Moreno, Pierre Deltenre.
Investigation: Pierre Deltenre.
Methodology: Pierre Deltenre.
Project administration: Pierre Deltenre.
Supervision: Pierre Deltenre.
Writing – original draft: Astrid Marot, Pierre Deltenre.
Writing – review & editing: Margaux Dubois, Eric Trépo, Christophe Moreno.

References
1. Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007. 45(6): 1348–54. https://doi.org/10.1002/hep.21607 PMID: 17518367
2. Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011. 365(19): 1790–800. https://doi.org/10.1056/NEJMoa1105703 PMID: 22070478
3. Artru F, Louvet A, and Mathurin P. Liver transplantation for patients with alcoholic hepatitis. Liver Int. 2017. 37(3): 337–339. https://doi.org/10.1111/liv.13248 PMID: 28240838
Liver transplantation for alcoholic hepatitis

4. Donckier V, Lucidi V, Gustot T, and Moreno C. Ethical considerations regarding early liver transplantation in patients with severe alcoholic hepatitis not responding to medical therapy. J Hepatol. 2014. 60(4): 866–71. https://doi.org/10.1016/j.jhep.2013.11.015 PMID: 24291238

5. Stroh G, Rosell T, Dong F, and Forster J. Early liver transplantation for patients with acute alcoholic hepatitis: public views and the effects on organ donation. Am J Transplant. 2015. 15(6): 1598–604. https://doi.org/10.1111/ajt.13176 PMID: 25707427

6. Im GY, Kim-Schlüger L, Shenoy A, Schubert E, Goel A, Friedman SL, et al. Early Liver Transplantation for Severe Alcoholic Hepatitis in the United States—A Single-Center Experience. Am J Transplant. 2016. 16(3): 841–9. https://doi.org/10.1111/ajt.13586 PMID: 26710309

7. Lee BP, Chen PH, Haugen C, Hernández R, Gurakar A, Philosophe B, et al. Three-year Results of a Pilot Program in Early Liver Transplantation for Severe Alcoholic Hepatitis. Ann Surg. 2017. 265(1): 20–29. https://doi.org/10.1097/SLA.0000000000001831 PMID: 27280501

8. DiMartini A, Day N, Dew MA, Javed L, Fitzgerald MG, Jain A, et al. Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease. Liver Transpl. 2006. 12(5): 813–20. https://doi.org/10.1002/lt.20688 PMID: 16528710

9. Foster PF, Fabrega F, Karademir S, Sankary HN, Mittal D, and Williams JW. Prediction of abstinence from ethanol in alcoholic patients following liver transplantation. Hepatology. 1997. 25(6): 1469–1477. https://doi.org/10.1002/hep.510250627 PMID: 9185770

10. Immordino G, Gelli M, Ferrante R, Ferrari C, Piaggio F, Ghinolfi D, et al. Alcohol abstinence and orthotopic liver transplantation in alcoholic liver cirrhosis. Transplant Proc. 2009. 41(4): 1253–5. https://doi.org/10.1016/j.transproceed.2009.03.092 PMID: 19460531

11. Tome S, Martinez-Rey C, Gonzalez-Quintela A, Gude F, Brage A, Otero E, et al. Influence of superimposed alcoholic hepatitis on the outcome of liver transplantation for end-stage alcoholic liver disease. J Hepatol. 2002. 36(6): 793–9. PMID: 12044530

12. Margulis AV, Pladevall M, Riera-Guardia N, Varas-Lorenzo C, Hazell L, Berkman ND, et al. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank. Clin Epidemiol. 2014. 6: 359–68. https://doi.org/10.2147/CLEP.S66677 PMID: 25336990

13. DerSimonian R and Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986. 7(3): 177–88. PMID: 3802833

14. Deltenre P, Trepo E, Rudler M, Monesscillo A, Fraga M, Denys A, et al. Early transjugular intrahepatic portosystemic shunt in cirrhotic patients with acute variceal bleeding: a systematic review and meta-analysis of controlled trials. Eur J Gastroenterol Hepatol. 2015. 27(9): e1–9. https://doi.org/10.1097/MEG.0000000000000403 PMID: 26049710

15. Marot A, Trepo E, Doerig C, Moreno C, Moradpour D, and Deltenre P. Systematic review with meta-analysis: self-expanding metal stents in patients with cirrhosis and severe or refractory oesophageal variceal bleeding. Aliment Pharmacol Ther. 2015. 42(11–12): 1250–60. https://doi.org/10.1111/apt.13176 PMID: 25707427

16. Marot A, Trepo E, Doerig C, Schoepfer A, Moreno C, and Deltenre P. Liver stiffness and platelet count for identifying patients with compensated liver disease at low risk of variceal bleeding. Liver Int. 2016. 37(5): 707–716. https://doi.org/10.1111/liv.13318 PMID: 27862856

17. Deeks JJ, Altman DG, and Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis, in Systematic reviews in health care-meta-analysis in context, D.S.G. Egger M, Altman DG, Editor. 2005, BMJ Books: London. p. 285–312.

18. Higgins JP, Thompson SG, Deeks JJ, and Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003. 327(7414): 557–60. https://doi.org/10.1136/bmj.327.7414.557 PMID: 12958120

19. Begg CB and Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994. 50(4): 1088–101. PMID: 7786990

20. Hanounah IA, Humbershaw A, Fiorita AL, McCullough AJ, O’Shea R, Rosenbaum C, et al. Ohio solid organ transplantation consortium (OSOTC) exception criteria for early liver transplantation (LT) in severe alcoholic hepatitis. Hepatology. 2014. 60: 258A–259A.

21. Im GY, Shenoy A, Schubert E, Goel A, Nahas J, Kim-Schlüger L, et al. Early liver transplantation for severe alcoholic hepatitis in the United States: a 4.5 year single-center experience. Hepatology. 2016. 63: 687A–688A.

22. Shakil AO, Pinna A, Demetris J, Lee RG, Fung JJ, and Rakela J. Survival and quality of life after liver transplantation for acute alcoholic hepatitis. Liver Transplantation and Surgery. 1997. 3(3): 240–244. PMID: 9346746

23. Siddachari RC, Goyal N, Wadhwana M, and Guptha S. Living donor liver transplantation for alcoholic steatohepatitis: survival and recidivism. Liver Transplantation. 2014. 20: S328.
24. Singal AK, Bashar H, Anand BS, Jampana SC, Singal V, and Kuo YF. Outcomes after liver transplantation for alcoholic hepatitis are similar to alcoholic cirrhosis: exploratory analysis from the UNOS database. Hepatology. 2012. 55(5): 1398–405. https://doi.org/10.1002/hep.25544 PMID: 22213344

25. Van Thiel DH, Bonet H, Gavaler J, and Wright HI. Effect of alcohol use on allograft rejection rates after liver transplantation for alcoholic liver disease. Alcohol Clin Exp Res. 1995. 19(5): 1151–5. PMID: 8561284

26. Wells JT, Said A, Agni R, Tome S, Hughes S, Dureja P, et al. The impact of acute alcoholic hepatitis in the explanted recipient liver on outcome after liver transplantation. Liver Transpl. 2007. 13(12): 1728–35. https://doi.org/10.1002/lt.21298 PMID: 18044757

27. Hasanin M, Dubay DA, McGuire BM, Schiano T, and Singal AK. Liver transplantation for alcoholic hepatitis: A survey of liver transplant centers. Liver Transpl. 2015. 21(11): 1449–52. https://doi.org/10.1002/lt.24208 PMID: 26136401

28. Pageaux GP, Bismuth M, Perney P, Costes V, Jaber S, Possoz P, et al. Alcohol relapse after liver transplantation for alcoholic liver disease: Does it matter? Journal of Hepatology. 2003. 38(5): 629–634. PMID: 12713874